PubRank

H Phillip Koeffler

Author PubWeight™ 311.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011 11.44
2 Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007 4.52
3 Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005 4.36
4 Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009 3.80
5 BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011 3.63
6 The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006 2.71
7 Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 2010 2.47
8 Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis 2009 2.34
9 Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002 2.33
10 Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 2007 2.31
11 Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013 2.14
12 Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005 2.06
13 Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002 2.03
14 Differentiation therapy of leukemia: 3 decades of development. Blood 2009 2.02
15 Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 2004 1.99
16 Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004 1.96
17 AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007 1.95
18 Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci U S A 2002 1.92
19 Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004 1.85
20 SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012 1.85
21 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006 1.82
22 Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2007 1.79
23 BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med 2013 1.79
24 Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res 2006 1.74
25 Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007 1.72
26 Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 2010 1.70
27 Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 2004 1.68
28 In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. Int J Cancer 2007 1.64
29 C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res 2002 1.64
30 Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002 1.60
31 Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma. Leuk Res 2005 1.56
32 BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med 2010 1.56
33 High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res 2009 1.53
34 Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem 2007 1.53
35 Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 2007 1.53
36 Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004 1.50
37 Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 2003 1.50
38 Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005 1.45
39 Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res 2006 1.45
40 The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol 2004 1.43
41 Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009 1.43
42 Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood 2003 1.40
43 Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002 1.37
44 Myelodysplastic syndrome. Annu Rev Med 2005 1.37
45 A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 2007 1.36
46 Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007 1.36
47 Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 2005 1.35
48 A role for the clock gene per1 in prostate cancer. Cancer Res 2009 1.35
49 Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci U S A 2008 1.34
50 Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 2006 1.33
51 Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 2006 1.32
52 Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBP epsilon and PU.1. Blood 2002 1.32
53 Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem 2003 1.31
54 Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 2008 1.30
55 HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 2005 1.28
56 Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004 1.28
57 Characterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathway. J Biol Chem 2003 1.27
58 Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res 2007 1.26
59 FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer 2007 1.25
60 Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem 2004 1.25
61 Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 2004 1.25
62 Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005 1.23
63 Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem 2003 1.23
64 Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates. BMC Genomics 2009 1.22
65 Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 2002 1.21
66 The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006 1.20
67 SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 2006 1.20
68 Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002 1.20
69 Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. Oncogene 2004 1.19
70 Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer. Breast Cancer Res Treat 2007 1.19
71 Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 2003 1.18
72 Expression of C/EBPbeta from the C/ebpalpha gene locus is sufficient for normal hematopoiesis in vivo. Blood 2002 1.18
73 Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 2009 1.17
74 Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003 1.17
75 Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther 2010 1.16
76 Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One 2011 1.16
77 Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer 2008 1.16
78 Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin Cancer Res 2005 1.15
79 ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol 2008 1.15
80 Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 2005 1.15
81 Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci 2006 1.15
82 Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 2004 1.15
83 Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines. Leuk Res 2006 1.13
84 Macrophage functional maturation and cytokine production are impaired in C/EBP epsilon-deficient mice. Blood 2002 1.13
85 HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004 1.13
86 C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene 2005 1.12
87 TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 2002 1.12
88 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005 1.12
89 Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 2002 1.12
90 Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res 2005 1.12
91 Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer 2009 1.12
92 HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther 2004 1.11
93 Allelotype analysis in relapsed childhood acute lymphoblastic leukemia. Oncogene 2003 1.11
94 Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 2007 1.10
95 CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50. Mol Cancer Res 2005 1.10
96 Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol 2009 1.10
97 Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol 2008 1.09
98 Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res 2006 1.09
99 Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 2003 1.09
100 Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res 2007 1.08
101 SOX7 is down-regulated in lung cancer. J Exp Clin Cancer Res 2013 1.08
102 CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res 2005 1.08
103 MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res 2008 1.08
104 1alpha,25-(OH)(2)-D(3) and its synthetic analogue decrease tumor load in the Apc(min) Mouse. Cancer Res 2002 1.08
105 Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol 2011 1.07
106 Identification of interaction partners and substrates of the cyclin A1-CDK2 complex. J Biol Chem 2004 1.06
107 CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood 2002 1.06
108 Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas. Clin Cancer Res 2008 1.06
109 Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol 2008 1.05
110 An emerging role of PARK2 in cancer. J Mol Med (Berl) 2013 1.05
111 Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest 2009 1.04
112 Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 2006 1.04
113 Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol 2003 1.04
114 Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer 2010 1.04
115 Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci 2008 1.03
116 BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene 2002 1.02
117 EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res 2011 1.02
118 Vitamin D compounds: activity against microbes and cancer. Anticancer Res 2006 1.01
119 The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol 2004 1.01
120 Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 2006 1.01
121 Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3. Blood 2012 1.00
122 Regulation of the CAMP gene by 1,25(OH)2D3 in various tissues. J Steroid Biochem Mol Biol 2006 1.00
123 Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 2008 1.00
124 Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica 2009 0.99
125 Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms. Clin Cancer Res 2010 0.98
126 Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One 2013 0.98
127 RACK1 promotes non-small-cell lung cancer tumorigenicity through activating sonic hedgehog signaling pathway. J Biol Chem 2012 0.98
128 Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol 2010 0.98
129 Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol Carcinog 2013 0.97
130 Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia. Int J Oncol 2009 0.97
131 Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int J Cancer 2014 0.97
132 Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Exp Hematol 2009 0.97
133 Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy. J Cell Biochem 2008 0.96
134 Discovery of over-expressed genes and genetic alterations in breast cancer cells using a combination of suppression subtractive hybridization, multiplex FISH and comparative genomic hybridization. Int J Oncol 2002 0.96
135 Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol 2005 0.96
136 Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Int J Oncol 2007 0.96
137 C/EBPepsilon interacts with retinoblastoma and E2F1 during granulopoiesis. Blood 2003 0.96
138 Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. J Steroid Biochem Mol Biol 2006 0.96
139 Cutaneous papilloma and squamous cell carcinoma therapy utilizing nanosecond pulsed electric fields (nsPEF). PLoS One 2012 0.96
140 RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation. Exp Hematol 2007 0.95
141 Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. Int J Cancer 2009 0.95
142 Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci U S A 2013 0.95
143 Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma. Int J Cancer 2009 0.94
144 Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK. Int J Oncol 2007 0.94
145 Neutrophil specific granule deficiency and mutations in the gene encoding transcription factor C/EBP(epsilon). Curr Opin Hematol 2002 0.94
146 DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr Pharm Biotechnol 2006 0.94
147 Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res 2008 0.94
148 Vitamin D compounds in leukemia. J Steroid Biochem Mol Biol 2005 0.94
149 Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 2008 0.93
150 Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagn Mol Pathol 2003 0.93
151 Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood 2006 0.93
152 Identifying progression-associated genes in adult T-cell leukemia/lymphoma by using oligonucleotide microarrays. Int J Cancer 2004 0.93
153 Vitamin D3 analogs stimulate hair growth in nude mice. Endocrinology 2002 0.92
154 Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk Res 2007 0.92
155 Progression of myelodysplastic syndrome: allelic loss on chromosomal arm 1p. Br J Haematol 2003 0.92
156 Analyses for binding of the transferrin family of proteins to the transferrin receptor 2. Br J Haematol 2004 0.92
157 Nanoelectropulse intracellular perturbation and electropermeabilization technology: phospholipid translocation, calcium bursts, chromatin rearrangement, cardiomyocyte activation, and tumor cell sensitivity. Conf Proc IEEE Eng Med Biol Soc 2005 0.92
158 Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer 2011 0.92
159 Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia. Haematologica 2010 0.91
160 Altered apoptosis pathways in mantle cell lymphoma. Leuk Lymphoma 2004 0.91
161 Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 2004 0.91
162 Phenotypic and functional alterations of peripheral blood monocytes in neutrophil-specific granule deficiency. J Leukoc Biol 2003 0.91
163 KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol 2014 0.91
164 Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood 2004 0.90
165 The correlation pattern of acquired copy number changes in 164 ETV6/RUNX1-positive childhood acute lymphoblastic leukemias. Hum Mol Genet 2010 0.90
166 Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBPbeta-deficient hematopoietic cells. Blood 2007 0.90
167 Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 2003 0.90
168 Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR. J Clin Endocrinol Metab 2013 0.90
169 Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood 2008 0.90
170 In vivo deficiency of both C/EBPβ and C/EBPε results in highly defective myeloid differentiation and lack of cytokine response. PLoS One 2010 0.89
171 Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells. Haematologica 2009 0.89
172 A Role for the PPARgamma in Cancer Therapy. PPAR Res 2008 0.89
173 Chronic phase of ETV6-ABL1 positive CML responds to imatinib. Genes Chromosomes Cancer 2008 0.89
174 Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells. Exp Hematol 2002 0.89
175 The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells. Oncogene 2004 0.89
176 Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2007 0.88
177 Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo. Exp Hematol 2010 0.88
178 Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk Res 2005 0.88
179 Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Cancer Chemother Pharmacol 2013 0.87
180 Adaptor protein Lnk associates with Tyr(568) in c-Kit. Biochem J 2008 0.87
181 SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F. Br J Haematol 2013 0.87
182 Identification of murine and human XCP1 genes as C/EBP-epsilon-dependent members of FIZZ/Resistin gene family. Oncogene 2004 0.87
183 Aberrant expression of neutrophil and macrophage-related genes in a murine model for human neutrophil-specific granule deficiency. J Leukoc Biol 2005 0.87
184 Adaptor protein Lnk inhibits c-Fms-mediated macrophage function. J Leukoc Biol 2010 0.87
185 Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN. Am J Hematol 2011 0.87
186 Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling. Exp Hematol 2011 0.87
187 Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia. Int J Oncol 2003 0.86
188 Novel Gemini vitamin D(3) analogs have potent antitumor activity. J Steroid Biochem Mol Biol 2008 0.86
189 DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog 2003 0.86
190 Retinoic acid regulates C/EBP homologous protein expression (CHOP), which negatively regulates myeloid target genes. Blood 2004 0.86
191 ATF4 differentially regulates transcriptional activation of myeloid-specific genes by C/EBPepsilon and C/EBPalpha. J Leukoc Biol 2007 0.86
192 Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells. Anticancer Res 2009 0.86
193 TMEFF1 and brain tumors. Oncogene 2003 0.86
194 Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer 2011 0.86
195 Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways. Oncol Rep 2006 0.86
196 Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. Leuk Res 2005 0.85
197 CCAAT/enhancer binding protein epsilon: changes in function upon phosphorylation by p38 MAP kinase. Blood 2005 0.85
198 Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin. Int J Oncol 2007 0.85
199 Imprinting status of DLK1 gene in brain tumors and lymphomas. Int J Oncol 2004 0.85
200 SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood 2009 0.85
201 Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. Gynecol Oncol 2010 0.85
202 Functional analysis of a novel DNA polymorphism of a tandem repeated sequence in the asparagine synthetase gene in acute lymphoblastic leukemia cells. Leuk Res 2008 0.85
203 Repression of the TMEFF2 promoter by c-Myc. J Mol Biol 2003 0.85
204 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res 2005 0.85
205 Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells. Cancer Lett 2003 0.85
206 RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene 2004 0.85
207 Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. Cell Cycle 2006 0.85
208 The cellular response to PPARgamma ligands is related to the phenotype of neuroblastoma cell lines. Oncol Res 2004 0.84
209 Receptor-targeted quantum dots: fluorescent probes for brain tumor diagnosis. J Biomed Opt 2007 0.84
210 RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin Cancer Res 2004 0.84
211 Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells. Oncol Rep 2008 0.84
212 Effect of ligands of nuclear hormone receptors on sodium/iodide symporter expression and activity in breast cancer cells. Breast Cancer Res Treat 2003 0.83
213 Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors. Oncogene 2002 0.83
214 PC-SPES inhibits colon cancer growth in vitro and in vivo. Cancer Res 2002 0.83
215 Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol 2013 0.83
216 Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res 2008 0.83
217 C/EBPε mediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice. J Clin Invest 2012 0.83
218 Methylation of the MLH1 gene in hematological malignancies. Oncol Rep 2005 0.83
219 Frameshift mutations in caspase-5 and other target genes in leukemia and lymphoma cell lines having microsatellite instability. Leuk Res 2003 0.83
220 Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Int J Oncol 2007 0.83
221 SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway. J Pathol 2014 0.83
222 PC-SPES: a potent inhibitor of nuclear factor-kappa B rescues mice from lipopolysaccharide-induced septic shock. Mol Pharmacol 2003 0.83
223 Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia. Leuk Res 2011 0.82
224 Identification of a new GLC1A mutation in a sporadic, primary open-angle glaucoma in Japan. Int J Mol Med 2003 0.82
225 The induction of apoptosis by a combined 1,25(OH)2D3 analog, EB1089 and TGF-beta1 in NCI-H929 multiple myeloma cells. Int J Oncol 2002 0.82
226 The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. Int J Cancer 2012 0.82
227 Protein partners of C/EBPepsilon. Exp Hematol 2004 0.82
228 Expression of the adaptor protein Lnk in leukemia cells. Exp Hematol 2009 0.82
229 Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays. Stem Cells 2005 0.81
230 CYR61: a new measure of lung cancer outcome. Cancer Invest 2007 0.81
231 Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol Rep 2004 0.81
232 Genetic polymorphisms in the tumour necrosis factor locus in childhood acute lymphoblastic leukaemia. Br J Haematol 2002 0.81
233 Do cancer cells selectively mutate HFE to increase their intracellular iron? Oncol Rep 2005 0.80
234 Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma. Leuk Lymphoma 2012 0.80
235 Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis. Oncol Lett 2011 0.80
236 Expression of bactericidal/permeability-increasing protein requires C/EBP epsilon. Int J Hematol 2007 0.80
237 Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor alpha/gamma, in human breast cancer cells. Mol Cancer Ther 2009 0.80
238 KLF6: mutational analysis and effect on cancer cell proliferation. Int J Oncol 2007 0.80
239 CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Mol Endocrinol 2011 0.79
240 PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells. Int J Oncol 2003 0.79
241 Per2 is a C/EBP target gene implicated in myeloid leukemia. Integr Cancer Ther 2009 0.79
242 NADE (p75NTR-associated cell death executor) suppresses cellular growth in vivo. Int J Oncol 2003 0.79
243 Modulation of DNA binding properties of CCAAT/enhancer binding protein epsilon by heterodimer formation and interactions with NFkappaB pathway. Blood 2007 0.79
244 An AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but from neutrophils in normal and infected conditions. Clin Exp Nephrol 2014 0.79
245 Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cells. Leuk Res 2006 0.79
246 Mxi1 isoforms are expressed in hematological cell lines and normal bone marrow. Int J Oncol 2005 0.79
247 Double minute chromosomes containing MYB gene and NUP214-ABL1 fusion gene in T-cell leukemia detected by single nucleotide polymorphism DNA microarray and fluorescence in situ hybridization. Leuk Res 2008 0.79
248 Genomic characterization of human and rat prolactinomas. Endocrinology 2012 0.79
249 Transcription factors in hematopoietic malignancies. Curr Opin Genet Dev 2007 0.78
250 Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines. Int J Oncol 2010 0.78
251 Novel Gemini vitamin D3 analogs: large structure/function analysis and ability to induce antimicrobial peptide. Int J Cancer 2013 0.78
252 Mouse models of colorectal cancer. Chin J Cancer 2011 0.78
253 Successive increases in human cyclin A1 promoter activity during spermatogenesis in transgenic mice. Int J Mol Med 2003 0.78
254 Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft. J Clin Endocrinol Metab 2014 0.78
255 Genome-wide Mapping of Copy Number Variations Using SNP Arrays. Transfus Med Hemother 2009 0.78
256 HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24. Leuk Res 2006 0.78
257 Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis. Blood 2002 0.78
258 PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells. Int J Oncol 2006 0.78
259 PC-SPES decreases proliferation and induces differentiation and apoptosis of human acute myeloid leukemia cells. Int J Oncol 2003 0.78
260 Discovery of stage-related proteins in esophageal squamous cell carcinoma using proteomic analysis. Proteomics Clin Appl 2007 0.77
261 Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors. Int J Hematol 2003 0.77
262 ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib. Cancer Sci 2006 0.77
263 Iron deficiency can upregulate expression of transferrin receptor at both the mRNA and protein level. Br J Haematol 2002 0.77
264 Mutations in the retinoblastoma-related gene RB2/p130 in adult T-cell leukaemia/lymphoma. Leuk Lymphoma 2003 0.77
265 Blockade of MEK signaling potentiates 5-Aza-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells. Int J Cancer 2009 0.77
266 Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib. Leuk Res 2009 0.77
267 Vitamin D analogs and breast cancer. Recent Results Cancer Res 2003 0.77
268 Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysis. Leuk Res 2011 0.75
269 Genetic differences between Asian and Caucasian chronic lymphocytic leukemia. Int J Oncol 2013 0.75
270 Methylenetetrahydrofolate reductase genotype does not play a role in adult T-cell leukemia/lymphoma pathogenesis among human T-lymphotrophic virus type 1 carriers. Leuk Res 2004 0.75
271 Roles of transferrin receptors in erythropoiesis. Rinsho Ketsueki 2016 0.75
272 Allelic loss during progression of follicular lymphoma. Leuk Res 2004 0.75
273 Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget 2017 0.75
274 The synthetic furanonaphthoquinone induces growth arrest, apoptosis and differentiation in a variety of leukaemias and multiple myeloma cells. Br J Haematol 2005 0.75
275 Important features of myelodysplastic syndrome. Int J Hematol 2002 0.75
276 Differentiation therapy for myelodysplastic syndrome. Clin Cancer Res 2002 0.75